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Abstract
Background: There is no consensus regarding the optimal adjuvant treatment after resection of
non-pancreatic periampullary adenocarcinoma (NPPC; distal common bile duct, ampulla, duodenum).
Objectives: The present study was conducted to evaluate the impacts on longterm survival and
recurrence of adjuvant intra-arterial chemotherapy (IAC) and concomitant radiotherapy (RT) in patients
submitted to resection for NPPC or pancreatic ductal adenocarcinoma (PDAC) in a randomized
controlled trial.
Methods: A total of 120 patients with PDAC (n = 62) or NPPC (n = 58) were prestratified at a ratio of
1:1 for tumour origin and randomized. Half of these patients were treated with adjuvant IAC/RT and
the other half were treated with surgery alone. Follow-up was completed for all patients up to 5 years
after resection or until death.
Results: There was no survival benefit in either the whole group (primary endpoint) or the PDAC
group after IAC/RT. In the NPPC group, longterm survival was observed in 10 patients in the IAC/RT
group and five patients in the control group: median survival was 37 months and 28 months, respec-
tively. The occurrence of liver metastases was reduced by IAC/RT from 57% to 29% (P = 0.038). Cox
regression analysis revealed a substantial effect of IAC/RT on survival (hazard ratio: 0.44, 95% confi-
dence interval 0.23–0.83; P = 0.011).
Conclusions: This longterm analysis shows that median and longterm survival were improved after
IAC/RT in patients with NPPC, probably because of the effective and sustained reduction of liver
metastases. The present results illustrate that NPPC requires an adjuvant approach distinct from that
in pancreatic cancer and indicate that further investigation of this issue is warranted.
Received 20 August 2014; accepted 13 January 2015
Correspondence
Casper H. J. van Eijck, Department of Surgery, Erasmus University Medical Centre, Dr Molewaterplein
40, 3015 GD Rotterdam, the Netherlands. Tel: + 31 10 463 4788. Fax: + 31 10 463 3507. E-mail:
c.vaneijck@erasmusmc.nl
Introduction
The treatment of adenocarcinoma of the pancreas and periam-
pullary region remains challenging. Even in the few patients
with disease suitable for resection with curative intent, overall
survival remains poor. Most tumours arise in the pancreatic
head near the ampulla of Vater. The majority of these tumours
represent pancreatic ductal adenocarcinoma (PDAC). Less fre-
quently, tumours in the pancreatic head region arise from the
distal common bile duct, ampulla of Vater and duodenum,
and are collectively known as periampullary cancers.1 Although
histologically very similar, these tumours bear a more favour-
able prognosis. The common assumption is that these tumours
are diagnosed at an earlier stage because they lead to jaundice
early as a result of their anatomical location. For these reasons
non-pancreatic periampullary adenocarcinoma (NPPC) may be
amenable to surgical resection more frequently than its pancre-
atic counterpart. However, evidence that NPPC represents a
separate family of tumours with different biological behaviour
is increasing.
Currently, evidence supports the administration of adjuvant
chemotherapy after resection for PDAC.2 There is no clear
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evidence to recommend adjuvant therapy after resection for
NPPC.3,4 The present paper reports a single-centre randomized
trial in which outcomes after adjuvant treatment with intra-
arterial chemotherapy (IAC) and concomitant radiotherapy
(RT) were compared with those after surgery alone. The choice
of IAC was supported by several small Phase I and II trials
showing promising results for a 5-fluorouracil (5-FU), mito-
xantrone and cisplatinum-based IAC regimen in advanced and
resected pancreatic cancer.5–7 Radiotherapy was added to
prevent local recurrence.
In a protocol similar to that of the well-known European
Organization for Research and Treatment of Cancer (EORTC)
trial3,8 and – at the start of the trial – in the absence of any
available evidence-based standard adjuvant treatment for either
group, patients with NPPC and PDAC were included in this
trial on an equal basis. Patients were prestratified for either
NPPC or PDAC after surgical resection. In 2008, shortly after
the inclusion of the last patient, the first results were
published.9 These showed the study’s inability to demonstrate
a survival benefit in PDAC. However, adjuvant IAC/RT
reduced the number of patients with NPPC who developed
liver metastases. Subsequent to this publication, discussion
ensued as to whether this was just a temporary effect or
whether such treatment might actually lead to better longterm
survival. The current paper presents longterm data from this
randomized controlled trial, in which all patients were followed
for at least 5 years or until death, with special focus on NPPC.
Materials and methods
The study design was described in detail in the primary analysis.9
The trial was approved by the local medical ethics committee.
Patients were randomized after resection into two groups
according to whether they were to be treated with IAC/RT or
not. All specimens were reviewed by one specialized pathologist
(HvD), and graded and staged according to the 2002 guidelines
of the Union for International Cancer Control (UICC).10
Tumour origin was determined according to the micro- and
macroscopic evaluation of the resected specimen. Duodenal, cys-
tic and neuroendocrine tumours were excluded. Other exclusion
criteria were: age >75 years; a Karnofsky index of ≤50; uncon-
trolled infection; previous chemo- or radiotherapy, and an aber-
rant vascular supply to the liver. Enrolled patients were
prestratified for tumour origin (PDAC or NPPC). After recovery
from surgery, patients were randomized during their first visit to
the outpatient clinic, according to a computer-generated ran-
domization list provided by the trial statistician. Treatment
started within 6–12 weeks after surgery. Patients with complica-
tions resulting in a prolonged hospital stay were not randomized.
During or before the first IAC administration and before radio-
therapy, all patients were restaged by computed tomography
(CT). Follow-up consisted of clinical and laboratory examina-
tions every 3 months. During the first 2 years, CT was per-
formed every 3 months and subsequently every 6 months.
Clinical signs of recurrence were indications for additional imag-
ing. All patients were monitored for 5 years or until death. All
survival data were cross-checked with the national population
registry.
Adjuvant treatment
The treatment schedule has been described in full detail previ-
ously.9 Chemotherapy was administered through a catheter
placed in the coeliac trunk and left in place during the five
treatment days of each cycle. Heparin was infused to prevent
thrombosis. Cycles consisted of mitoxantrone on day 1,
followed by 5-FU/folinic acid on days 2–4 and cisplatinum on
day 5. Toxicity was monitored and the dose was reduced by
20% in the event of toxicity of greater than World Health
Organization (WHO) Grade II toxicity. After 2 weeks radio-
therapy was started. A total cumulative dose of 54 Gy was
delivered in single doses of 1.8 Gy on 5 days per week. Intra-
arterial chemotherapy was continued for up to a total of six
cycles with intervals of 4 weeks between cycles. Therapy was
discontinued in the event of serious toxicity (WHO Grades III
and IV) (Table 1).
Statistics
The primary outcome was overall survival. Secondary endpoints
were toxicity and disease-free survival. Using an a-value of 0.05
(two-sided) and a b-value of 0.10, and prestratification by
Table 1 Cycles of intra-arterial chemotherapy and concomitant radiotherapy (IAC/RT) administered in 28 patients resected for
non-pancreatic periampullary adenocarcinoma (NPPC) and reasons for cessation of therapy. Over half (n = 15) of all patients received all
six cycles
Cycles of IAC/RT
0 1 2 3 4 5 6 Total
Patients, n (%) 28 (100%) 25 (89%) 23 (82%) 18 (64%) 17 (61%) 16 (57%) 15 (54%) 28
Dropouts, n (%) 3 (11%) 2 (7%) 5 (18%) 1 (4%) 1 (4%) 1 (4%) 0 13 (46%)
Progression 1 (4%) 2 (7%) 3 (11%)
Angio-related 1 (4%) 1 (4%)
Toxicity 1 (4%) 2 (7%) 1 (4%) 1 (4%) 1 (4%) 6 (21%)
Patient factors 2 (7%) 1 (4%) 3 (11%)
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tumour origin, 120 patients were required to be enrolled in each
trial arm assuming 2-year survival rates of 30% in the control
groups and 50% in the experimental groups. Inclusion was
stopped after 120 patients because gemcitabine-based adjuvant
therapy had come to represent the standard of care for PDAC
and an observation-only group for PDAC was therefore consid-
ered unethical. Separate continuation of the trial for NPPC was
not part of the protocol and therefore not considered.
Analyses were performed on an intention-to-treat basis. IBM
SPSS Statistics for Windows Version 20.0 (IBM Corp., Armonk,
NY, USA) was used for the current analyses. The chi-squared
test was used in analyses of categorical variables. Student’s
t-test was used in analyses of continuous variables. A P-value
<0.05 (two-sided) was considered to indicate statistical signifi-
cance. All P-values were rounded to three decimals. Survival
was estimated using the Kaplan–Meier method. Significance
was calculated using the log-rank test.
In addition, near-significant factors (P < 0.100) from the
univariate analysis were entered in a multivariate Cox propor-
tional hazards model, in accordance with the criteria for pro-
portional hazards.11 Hazard ratios (HRs) are shown with 95%
confidence intervals (95% CIs). Grade variables were consid-
ered of ordinal level and therefore coded as dummy variables.
Overall survival and disease-free survival
Primary analysis (whole group, n = 120)
The primary analysis was based on 82 deaths. Longer follow-
up led to the registration of a further 18 events. Therefore, this
survival analysis is based on 100 deaths. Longterm survival
(defined as survival for >60 months) was observed in 19
patients. Median overall survival in patients with PDAC
(20 months) was lower than that in patients with NPPC
(32 months), regardless of therapy (P < 0.001). In the com-
bined groups (whole study group), IAC/RT did not improve
survival. Disease-free survival was longer in patients treated
with IAC/RT in the whole (PDAC and NPPC) study group
(13 months versus 8 months; P = 0.031). Results in each of
the prestratified groups are very different.
Subgroup PDAC (n = 62)
Concomitant radiotherapy did not influence survival in PDAC
(20 months versus 21 months; P = 0.929). There was no sig-
nificant effect of IAC/RT on time to progression in PDAC
alone (12 months versus 8 months; P = 0.214).
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Figure 1 Kaplan–Meier curves for overall survival in patients
submitted to resection of non-pancreatic periampullary
adenocarcinoma with (dotted line) and without (black line) intra-
arterial chemotherapy and concomitant radiotherapy (IAC/RT) (log-
rank test, P = 0.077; hazard ratio 0.44, 95% confidence interval
0.23–0.83; P = 0.011)
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Figure 2 Kaplan–Meier curves for overall survival according to
tumour differentiation in patients submitted to resection of well
(dotted line), moderate (black line) and poorly (dashed line)
differentiated non-pancreatic periampullary adenocarcinoma. Well
versus poorly differentiated, P < 0.01; well versus moderately
differentiated, P = 0.022; moderately versus poorly differentiated,
P = 0.122
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Subgroup NPPC (n = 58)
In the NPPC group, the number of patients who achieved
longterm survival after IAC/RT (n = 10) was twice that of
longterm survivors after surgery alone (n = 5). Although the
survival curves (Fig. 1) clearly diverge, log-rank analysis did
not indicate statistical significance (median actual survival of
37 months versus 28 months; P = 0.077). However, Cox
regression revealed a substantial effect of IAC/RT on survival
(HR 0.44, 95% CI 0.23–0.83; P = 0.011).
The other independent factor was differentiation grade.
Regardless of therapy, well-differentiated NPPC bore a more
favourable prognosis than moderately and poorly differentiated
NPPC (Fig. 2). A detailed description of univariate and multi-
variate analyses for overall survival is shown in Table 2.
Factors were tested for their independent contributions in
the model.
In patients with NPPC, time to progression appears to be
longer after adjuvant IAC/RT (19 months versus 8 months;
log-rank test, P = 0.103; HR for recurrent disease 0.48, 95% CI
0.25–0.90; P = 0.022) (Fig. 3). The other independent factor in
the same regression model was differentiation grade (Table 2).
Patterns of recurrence are shown in Table 3. Interestingly,
IAC/RT effectively suppressed the longterm occurrence of liver
metastases in patients with NPPC, from 17 to eight cases (HR
3.27, 95% CI 1.10.00–9.80; chi-squared test, P = 0.038). No
effect on time to occurrence of liver metastasis was shown.
Discussion
This is a detailed longterm outcome analysis of a randomized
clinical trial comparing survival after adjuvant therapy with
that after observation alone in patients submitted to resection
for PDAC or NPPC. The present findings confirm the results
of the original report that IAC/RT does not improve survival
in PDAC.9 The effect of IAC/RT in this group is disappointing
and confirms that true pancreatic cancer has a dismal progno-
sis despite the addition of chemotherapy and radiotherapy.
However, in patients with NPPC, survival appears to have been
better in the IAC/RT group. Intra-arterial chemotherapy and
radiotherapy also effectively reduced the occurrence of liver
metastases. This effect was sustained throughout the longterm
follow-up.
Table 2 Summary of univariate and multivariate analyses in patients submitted to resection of non-pancreatic periampullary
adenocarcinoma (NPPC)
Univariate and multivariate analyses: overall survival in NPPC
IAC/RT
group, n
Surgery only
group, n
Univariate (log-rank) Multivariate (Cox)
Median survival,
months
95% CI P-value HR 95% CI P-value
All patients 28 30
Male 11 17 21 17–25
Female 17 13 33 16–50 0.285
PPPD 22 23 28 13–43
Whipple 6 7 19 7–31 0.303
Pathology
T2 9 8 33 11–55 Reference
T3 13 16 28 10–47 0.435
T4 6 6 18 8–28 0.025
N0 12 12 36 23–49
N1 16 18 21 17–25 0.037
R0 23 29 25 13–36
R1 5 1 20 0–51 0.081
Differentiation
Good 4 5 60 – Reference
Moderate 17 19 24 7–36 0.022
Poor 7 6 20 7–33 0.003 2.55 1.53–4.25 0.000
Surgery only 30 21 17–26
Treatment IAC/RT 28 33 20–46 0.077 0.44 0.23–0.83 0.011
95% CI, 95% confidence interval; HR, hazard ratio; IAC/RT, intra-arterial chemotherapy and concomitant radiotherapy; N0, node-negative dis-
ease; N1, node-positive disease; PPPD, pylorus-preserving pancreaticoduodenectomy; R0, negative margin; R1, positive margin; T1–3, tumour
stage.
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The present results confirm that NPPCs probably represent
a separate family of tumours with different biological behav-
iour. This hypothesis is supported by the superior survival of
patients with NPPC, even after adjusting for tumour size, posi-
tive lymph nodes and stage.12,13 Evidence is mounting that
these tumours may have a different genetic basis and express
different proteins, microRNA and growth factor receptors.13–17
It may become possible in the future to use these biomarkers
to identify more specific subtypes of NPPC and PDAC and
select a more targeted type of adjuvant therapy.
In pursuit of the improvement of survival after surgery for
pancreatic cancer, several randomized trials offering adjuvant
chemotherapy both with and without concomitant radiother-
apy have been conducted. These have led to the consensus that
gemcitabine-based adjuvant chemotherapy improves outcomes
after surgery for PDAC.18 The role of adjuvant radiotherapy
remains doubtful.19
By contrast, the benefit of adjuvant chemotherapy in patients
with NPPC remains largely unclear. The first trial was the well-
known EORTC trial, which offered a 5-FU-based regimen with
concomitant radiotherapy, but which failed to shown an effect
on survival.3,8 In the EORTC trial, adjuvant chemotherapy based
on 5-FU with concomitant radiotherapy (40 Gy) was compared
with surgery alone. Liver metastases occurred in 50% of patients.
There were no significant differences in the occurrence of liver
metastases between treatment groups. Neoptolemos et al.4
published the only other recent randomized study on adjuvant
therapy for NPPC. This trial compared three study groups, in
which 5-FU-based chemotherapy, gemcitabine-based chemo-
therapy and surgery only, respectively, were administered. The
authors were unable to demonstrate improved survival after
gemcitabine- or 5-FU-based adjuvant chemotherapy in the
primary analysis.4 However, in a multivariate analysis, after
adjusting for variables of age, bile duct cancer, poor tumour
differentiation and positive lymph nodes, the authors observed a
modest benefit in association with adjuvant chemotherapy. This
study clearly shows that the common adjuvant schedules for
PDAC cannot be extrapolated to the treatment of NPPC. In the
recent ABC-2 trial,20 the provision of gemcitabine combined
with cisplatinum led to a survival benefit in patients with
advanced cholangiocarcinomas. The patients included in this
study suffered from a range of intrahepatic, extrahepatic and
metastastic bile duct cancers. Perhaps the addition of cisplati-
num might have evoked a response to IAC in the ampullary and
distal bile duct cancers (NPPC) investigated in the present study.
The rationale for using IAC/RT in the present study was
two-fold. Treatment was intended to facilitate the reduction of
liver metastases (IAC) and improve local control (RT). Indeed,
in patients with NPPC, the provision of IAC/RT led to a
reduction in the occurrence of liver metastases and had a sub-
stantial effect on median survival, disease-free survival and the
number of longterm survivors. Interestingly, the present
authors were unable to demonstrate an effect on local recur-
rence. The EORTC study also included radiotherapy, adminis-
tered at 40 Gy rather than the 54 Gy used in the present
study.8 The EORTC trial also failed to show any effect on local
recurrence. Therefore, it is more likely that the IAC, rather
than the radiotherapy, was responsible for reducing the num-
ber of liver metastases and consequently imposing a positive
effect on survival. Two Phase II clinical trials and a case study
preceded the present trial.5,21,22 Both trials showed a decrease
in the occurrence of liver metastases and improved survival
after IAC. The underlying principle is that by infusing selec-
tively, a much higher dose can be achieved in the target organ,
in this case the liver. The present findings do not preclude the
possibility that, in pancreatic cancers, the mitoxantrone, 5-FU
and cisplatinum combination used in this study may be infe-
rior to a gemcitabine-based regimen. Furthermore, recent
developments of new therapeutic agents and combination ther-
apy have led to more effective systemic therapy in metastatic
pancreatic cancer using a 5-FU, leucovorin, irinotecan and
oxaliplatin (FOLFIRINOX) regimen.23 The present authors
speculate that a different agent or combination may be effec-
tive as IAC in PDAC and suggest that the IAC concept should
not be completely discarded as a possible means of delivering
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Figure 3 Kaplan–Meier curves for disease-free survival in patients
submitted to resection of non-pancreatic periampullary
adenocarcinoma (NPPC) with (dotted line) and without (black line)
intra-arterial chemotherapy and concomitant radiotherapy (IAC/RT)
(19 months versus 8 months; log-rank test, P = 0.103; hazard ratio
for recurrent disease 0.48, 95% confidence interval 0.25–0.90;
P = 0.022)
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other more effective chemotherapeutics to patients suffering
from PDAC.
In the present study, Cox regression analysis showed that both
differentiation grade and adjuvant treatment were of independent
influence on overall and disease-free survival in NPPC.
Differentiation grade was inversely correlated with survival
(Fig. 2), which is concordant with findings in other studies.4
Survival after resection of well-differentiated cancers is much
better compared with that after resection of moderately or poorly
differentiated tumours. It is questionable whether well-differenti-
ated tumours should be treated with this adjuvant regimen.
This longterm analysis shows interesting effects of adjuvant
IAC/RT on survival in patients with NPPC, which were not
revealed in the primary analyses. Although this group was rela-
tively small (n = 58), and despite the premature conclusion of
the trial and the fact that a benefit was observed only in this
prestratified group, the present study provides some evidence
that this IAC/RT protocol may be beneficial in these patients.
It must be acknowledged that this study is underpowered.
However, a small group size is more likely to lead to a type II
error (i.e. no effect of therapy in the analyses although a true
effect may have been present) than an overestimation of the
effect of IAC/RT. The finding of a positive effect in a prestrati-
fied group advocates for the further study of this concept in
patients with NPPC, particularly in those with moderately or
poorly differentiated tumours. In addition, this is the only
study to date to show any substantial beneficial effect of adju-
vant therapy in this particular group of patients.
Although the IAC/RT protocol administered in the present
study was intense, it did not adversely affect quality of life
during the short time that some patients live after ‘curative’
resection.24 Toxicity was relatively mild. Delivering IAC to a
large number of patients is logistically challenging and requires
the training of medical staff and dedicated nurses. Further
developments in minimally invasive isolated perfusion devices
may prove to be more practical to use and more effective in
delivering chemotherapy to the liver alone, where the effect of
the present regimen was most noticeable.
In conclusion, patients with resectable NPPC may benefit
from adjuvant IAC as it has a substantial effect on overall and
disease-free survival, and effectively and enduringly reduces the
occurrence of liver metastases. The value of radiotherapy for
local control remains doubtful. The results of this trial warrant
further investigation by means of a dedicated trial on adjuvant
IAC for NPPC. This trial should enrol patients in three treat-
ment arms: (i) surgery only (control); (ii) systemic gemcitabine
plus cisplatinum (based on the ABC trial), and (iii) gemcita-
bine plus cisplatinum-based IAC.
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